Zhang Wen-Yi
Department of Hepatobiliary and Pancreatic Medicine and Interventional Medicine, The Second Hospital of Jilin University, Changchun, China.
Cancer Biother Radiopharm. 2025 May 21. doi: 10.1089/cbr.2025.0088.
Pancreatic cancer remains one of the most challenging malignancies to treat, characterized by limited therapeutic options and persistently poor survival rates. Conventional radiotherapy presents several limitations, including nonspecific tumor targeting, elevated toxicity to adjacent healthy tissues, and intrinsic radioresistant pancreatic tumors, necessitating innovative treatment strategies. In comparison to previous studies, which reported a median survival rate of 12 months for patients undergoing conventional radiotherapy, the results of this study demonstrate a significant improvement, with a median survival increase to 18 months using a novel targeted approach. Additionally, our findings show a 30% reduction in off-target tissue toxicity, compared with the 45% toxicity seen with traditional methods. Nanoparticle-enhanced radiotherapy (NERT) introduces a novel therapeutic approach using biocompatible nanoparticles functionalized with tumor-specific ligands. These nanoparticles serve as radiosensitizers, selectively increasing the local radiation dose within the tumor microenvironment while minimizing exposure normal tissues. This targeted delivery mechanism leverages precision nanotechnology to enhance the therapeutic index. Preclinical studies have shown NERT significantly improves treatment outcomes in pancreatic cancer. The method achieves 97.4% increase in treatment efficiency, 45.2% reduction in toxicity, 96.3% enhancement in patient outcomes, 40.3% decrease in systemic side-effects, and 98.6% improvement in tumor targeting when compared with conventional radiotherapy. These findings underscore the transformative potential of NERT in addressing key limitations of traditional pancreatic cancer treatments. By integrating precision targeting with advanced nanotechnology, NERT enhances the efficacy radiotherapy while mitigating adverse effects, thereby improving patient outcomes. This innovative modality holds promise for redefining clinical protocols and elevating standards of care in oncology. The proposed method achieves the treatment efficiency by 97.4%, toxicity by 45.2%, patient outcome by 96.3%, systematic side-effect by 40.3%, and tumor targeting by 98.6%.
胰腺癌仍然是最难治疗的恶性肿瘤之一，其特点是治疗选择有限且生存率一直很低。传统放疗存在若干局限性，包括肿瘤靶向性不特异、对邻近健康组织的毒性增加以及胰腺肿瘤本身具有放射抗性，因此需要创新的治疗策略。与之前报道的接受传统放疗患者的中位生存率为12个月的研究相比，本研究结果显示出显著改善，采用新型靶向方法后中位生存期增加到了18个月。此外，我们的研究结果表明，与传统方法45%的毒性相比，脱靶组织毒性降低了30%。纳米颗粒增强放疗（NERT）引入了一种新型治疗方法，即使用用肿瘤特异性配体功能化的生物相容性纳米颗粒。这些纳米颗粒用作放射增敏剂，在肿瘤微环境中选择性增加局部辐射剂量，同时使正常组织的暴露最小化。这种靶向递送机制利用精密纳米技术提高治疗指数。临床前研究表明，NERT可显著改善胰腺癌的治疗效果。与传统放疗相比，该方法的治疗效率提高了97.4%，毒性降低了45.2%，患者预后改善了96.3%，全身副作用减少了40.3%，肿瘤靶向性提高了98.6%。这些发现强调了NERT在解决传统胰腺癌治疗的关键局限性方面的变革潜力。通过将精确靶向与先进纳米技术相结合，NERT提高了放疗疗效，同时减轻了不良反应，从而改善了患者预后。这种创新模式有望重新定义临床方案并提高肿瘤学护理标准。所提出的方法实现了97.4%的治疗效率、45.2%的毒性、96.3%的患者预后、40.3%的全身副作用以及98.6%的肿瘤靶向性。
